Glucotrack (Lōkahi) advances LT-100, submits protocol; ai² platform flags 45 assets

Glucotrack, Inc.

Completed strategic business combination on July 14, 2026; Glucotrack Technologies now wholly owned subsidiary.
LT-100 for osteoarthritis knee pain: clinical protocol submitted for regulatory review; targeting near-term study start.
Planned study evaluates once-weekly subcutaneous injection vs historical 15 weekly intradermal injections.
ai² platform has 14 university partners, screening 12,000+ abandoned late-stage programs; 45 assets met initial criteria.
Qare first ai² Accelerator initiative; business model aims to monetize assets before registration trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.